A detailed history of Lazard Asset Management LLC transactions in Pyxis Oncology, Inc. stock. As of the latest transaction made, Lazard Asset Management LLC holds 369 shares of PYXS stock, worth $583. This represents 0.0% of its overall portfolio holdings.

Number of Shares
369
Previous 16,205 97.72%
Holding current value
$583
Previous $53,000 98.11%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.83 - $3.94 $44,815 - $62,393
-15,836 Reduced 97.72%
369 $1,000
Q2 2024

Aug 14, 2024

BUY
$3.06 - $5.58 $49,587 - $90,423
16,205 New
16,205 $53,000

Others Institutions Holding PYXS

About Pyxis Oncology, Inc.


  • Ticker PYXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,096,400
  • Market Cap $55.5M
  • Description
  • Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...
More about PYXS
Track This Portfolio

Track Lazard Asset Management LLC Portfolio

Follow Lazard Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.